

Subject: NEW UCSF-PFIZER CALL: 2 page proposals due April 21, 2017
Date: Tuesday, March 7, 2017 at 3:25:16 PM Pacific Standard Time
From: Research - Funding Opportunities (sent by UCSF Funding Opportunities <FUNDING_OPPTS@LISTSRV.UCSF.EDU>)
To: FUNDING_OPPTS@LISTSRV.UCSF.EDU



In 2016, UCSF renewed its partnership with Pfizer's Centers for Therapeutic Innovation (CTI). For over five years, UCSF and Pfizer CTI scientists have been working together to translate discoveries into novel therapeutics.

Two funding types/levels are available:

- **Early Proof-of-Concept funding.** For target(s) and/or mechanism(s) ideas in need of more validation. Typical project funding ranges from \$100,000 - \$150,000 for up to 12 months to awarded UCSF lab.
- **Multi-year joint programs to discovery new therapeutics.** Typical project funding range of \$200,000 - \$500,000 per year to awarded UCSF lab. For successful programs that produce therapeutics for clinical trial development, there are additional milestone and royalty payments to UCSF and investigators.

Therapeutic Areas

- **Oncology:** Immuno-oncology, targets that promote immune response, targets involved in oncogenic signaling and tumorigenesis, novel tumor-specific cell surface antigens or tumor targeting approach, tumor metabolism and epigenetics
- **Inflammation and immune disorders:** Rheumatoid Arthritis, lupus, Crohn's Disease and colitis, NASH, atopic dermatitis, cytokines and their signaling pathways, regulatory cells and tolerance induction, microbiome with an interest in epithelial barrier
- **Cardiovascular and metabolic diseases:** Cardiovascular disease and heart failure, NAFLD/NASH, and obesity/eating disorders
- **Neuroscience:** Alzheimer's Disease, Parkinson's Disease, chronic neuroinflammation mechanisms and mitochondrial biology impacting the pathologies of AD and PD, cerebral amyloid angiopathy and vascular impairment associated with neurodegeneration
- **Rare monogenic genetic diseases:** Hematologic (non-malignant), neuromuscular

and pulmonary diseases, including PAH and cystic fibrosis

Modalities

- **Large Molecules:** examples include antibodies, proteins, peptides, ADCs, Fusions)
- **Small Molecules:** target classes include kinases, GPCRs, ion channels, transporters, serine hydrolases, and epigenetic targets

What We Look For

- Association between target biology and disease mechanism
- Targets with potential to lead to differentiated medicines, especially for unmet medical needs

Please refer to the attached guidelines and pre-proposal template. Please contact me, Peter Kotsonis at peter.kotsonis@ucsf.edu for feedback and consultation on your submission. If needed, it is possible to schedule a non-confidential meeting with a Pfizer scientist to further develop any pre-proposal before submission.

NON-CONFIDENTIAL 2 page pre-proposals should be submitted by April 21, 2017 to Peter Kotsonis at peter.kotsonis@ucsf.edu

Use this link to [unsubscribe](#) from this mailing list.